Evaxion Biotech A/S (NASDAQ:EVAX) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX) in a research report released on Thursday,Benzinga reports. The firm currently has a $14.00 target price on the stock.

Separately, Lake Street Capital reduced their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th.

Evaxion Biotech A/S Trading Up 4.3 %

Evaxion Biotech A/S stock opened at $2.66 on Thursday. The firm’s 50-day moving average is $3.71 and its 200-day moving average is $9.67. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. Evaxion Biotech A/S has a 1 year low of $2.22 and a 1 year high of $22.05. The company has a market cap of $3.11 million, a P/E ratio of -1.83 and a beta of -0.28.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evaxion Biotech A/S stock. Invst LLC increased its position in Evaxion Biotech A/S (NASDAQ:EVAX) by 16.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 50,400 shares of the company’s stock after acquiring an additional 7,200 shares during the period. Invst LLC owned approximately 4.31% of Evaxion Biotech A/S worth $43,000 at the end of the most recent reporting period. 11.04% of the stock is currently owned by hedge funds and other institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.